Cardiff Oncology Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
32
- Stock Symbol
-
CRDF
- Investments
-
1
- Share Price
-
$0.73
- (As of Friday Closing)
Cardiff Oncology General Information
Description
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Contact Information
Website
www.cardiffoncology.comCorporate Office
- 11055 Flintkote Avenue
- San Diego, CA 92121
- United States
Corporate Office
- 11055 Flintkote Avenue
- San Diego, CA 92121
- United States
Cardiff Oncology Timeline
Cardiff Oncology Stock Performance
As of 13-Nov-2026, Cardiff Oncology’s stock price is $0.73. Its current market cap is $56.5M with 77.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.73 | $0.73 | $0.71 - $3.31 | $56.5M | 77.8M | 591K | -$0.54 |
Cardiff Oncology Financials Summary
As of 30-Sep-2026, Cardiff Oncology has a trailing 12-month revenue of $559K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 60,069 | 129,702 | 232,734 | (12,946) |
| Revenue | 559 | 593 | 683 | 488 |
| EBITDA | (38,624) | (48,051) | (47,747) | (45,112) |
| Net Income | (37,650) | (45,851) | (45,431) | (41,441) |
| Total Assets | 36,414 | 61,884 | 97,190 | 81,637 |
| Total Debt | 265 | 832 | 1,523 | 2,149 |
Cardiff Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cardiff Oncology Comparisons
Industry
Financing
Details
Cardiff Oncology Competitors (8)
One of Cardiff Oncology’s 8 competitors is ArriVent Biopharma, a Formerly VC-backed company based in Newtown Square, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA | ||||
| Verastem | Formerly VC-backed | Needham, MA | ||||
| GeneCast Biotechnology | Private Equity-Backed | Wuxi, China | ||||
| Erasca | Formerly VC-backed | San Diego, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Cardiff Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cardiff Oncology Patents
Cardiff Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112550-A1 | Breast cancer treatment | Pending | 24-Nov-2024 | ||
| US-20260116962-A1 | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | Pending | 30-Oct-2024 | ||
| WO-2026096660-A1 | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | Pending | 30-Oct-2024 | ||
| WO-2025240673-A1 | Cancer treatment using akt inhibitors and plk1 inhibitors | Pending | 15-May-2024 | ||
| US-20250275978-A1 | Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer | Inactive | 04-Mar-2024 | A61K31/519 |
Cardiff Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cardiff Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cardiff Oncology Acquisitions (1)
Cardiff Oncology’s most recent deal was a Merger/Acquisition with MultiGEN Diagnostics (Clinical Laboratory Assets) for . The deal was made on 01-Feb-2012.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MultiGEN Diagnostics (Clinical Laboratory Assets) | 01-Feb-2012 | Merger/Acquisition | Biotechnology |
Cardiff Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.05 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Cardiff Oncology FAQs
-
When was Cardiff Oncology founded?
Cardiff Oncology was founded in 1999.
-
Where is Cardiff Oncology headquartered?
Cardiff Oncology is headquartered in San Diego, CA.
-
What is the size of Cardiff Oncology?
Cardiff Oncology has 32 total employees.
-
What industry is Cardiff Oncology in?
Cardiff Oncology’s primary industry is Drug Discovery.
-
Is Cardiff Oncology a private or public company?
Cardiff Oncology is a Public company.
-
What is Cardiff Oncology’s stock symbol?
The ticker symbol for Cardiff Oncology is CRDF.
-
What is the current stock price of Cardiff Oncology?
As of 13-Nov-2026 the stock price of Cardiff Oncology is $0.73.
-
What is the current market cap of Cardiff Oncology?
The current market capitalization of Cardiff Oncology is $56.5M.
-
What is Cardiff Oncology’s current revenue?
The trailing twelve month revenue for Cardiff Oncology is $559K.
-
Who are Cardiff Oncology’s competitors?
ArriVent Biopharma, Verastem, GeneCast Biotechnology, Erasca, and CytomX Therapeutics are some of the 8 competitors of Cardiff Oncology.
-
What is Cardiff Oncology’s annual earnings per share (EPS)?
Cardiff Oncology’s EPS for 12 months was -$0.54.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
